A new study explains how pancreatic tumors use a sugar coating to hide from the immune system and shows that a newly ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning company’s expansion into oncology applications AMVs are a new class of ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

In a recent preclinical study, researchers from The University of Texas MD Anderson Cancer Center developed an antibody therapy called 77A that showed an ability to overcome treatment resistance in ...

Roche’s FDA approval of Lunsumio VELO as a one-minute subcutaneous bispecific therapy for relapsed or refractory follicular lymphoma marks a meaningful advance in reducing treatment burden while ...

A new research paper was published in Volume 16 of Oncotarget on July 9, 2025, titled "A novel anti-human CD25 mAb with preferential reactivity to activated T regulatory cells depletes them from the ...

Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese ...

DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication ...